IGFBP-7 (Insulin-like Growth Factor-binding Protein 7, IBP-7, IGF-binding Protein 7, IBP7, GFBP-rP1, MAC25 Protein, PGI2-stimulating Factor, Prostacyclin-stimulating Factor, Tumor-derived Adhesion Factor, TAF, IGFBP7, MA

Antibodies / Antibodies-Growth Factors, Cytokines

-20°C

Supplied as a lyophilized powder from PBS, pH 7.4, 0.1% BSA, 0.5% trehalose. Reconstitute with 100ul sterile dH2O.

Recombinant corresponding to mouse IGFBP7, expressed in Sf21 cells.

Unlike insulin, both IGF-I and IGF-II circulate in plasma tightly bound to specific binding proteins. Two major forms of IGF-binding proteins have been identified in human plasma, a low molecular weight form and a high molecular weight form. The low molecular weight IGF-binding protein (IGFBP1) is synthesized in liver, secretory endometrium, and decidua. It binds both IGF I and IGF II with high affinity. Insulin-like growth factor binding protein-1 (IGFBP-1 ~30kD; also known as IBP1 or placental protein 12, or IGF-BP25; chromosome 7p14-p12)) is a member of the superfamily of insulin-like growth factor (IGF) binding proteins which include six high-affinity IGF binding proteins (IGFBP1-6) and at least four low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). The IGFBP members are cysteine- rich proteins with conserved cysteine residues, clustered in the amino-terminal and the carboxy-terminal regions of the molecule. Contained within IGFBP-1 and -2 is an integrin receptor recognition sequence (RGD) that is responsible for promoting cell migration by an IGF-independent action. IGFBPs hold a central position in IGF ligand-receptor interactions through influences on both the bioavailability and distribution of IGFs in the extracellular environment. IGFBPs will either inhibit or enhance the biological activities of IGF or act in an IGF-independent manner.

Applications:
Suitable for use in ELISA. Other potential application, though not tested is Western Blot. Other applications not tested.

Recommended Dilution:
ELISA: 0.5-1ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized and reconstituted products are stable for 12 months after receipt at -20°C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.